<DOC>
	<DOCNO>NCT00041899</DOCNO>
	<brief_summary>This study compare blood level drug CDB-2914 healthy woman receive compound crystalline powder form blood level woman receive identical dose drug micronized form . Generally , absorption compound make crystalline powder less micronized compound , substance process many similar-sized particle . CDB-2914 manmade hormone similar hormone cortisol progesterone . The National Institute Child Health Human Development evaluate ability drug treat reproductive condition . Institute study show CDB-2914 increase time produce mature egg ovary , cause early menstrual period , CDB-2914 might use treat fibroid endometriosis pain . As part evaluation purpose , study determine absorption crystalline micronized powder form CDB-2914 result blood level drug . Women 18 50 year age good health may eligible study . Premenopausal woman must pregnant ( determined urine pregnancy test ) breastfeeding must practice birth control study . Candidates screen medical history , physical examination , blood urine test . Women use IUD contraception advise also use barrier contraceptive ( diaphragm condom ) week take CDB-2914 . Participants admit NIH Clinical Center inpatient service outpatient day hospital twice pharmacokinetic study ( blood draw measure blood level CDB-2914 single dose drug ) . They come Clinical Center 7:00 a.m. catheter ( thin plastic tube ) insert arm vein draw blood first 24 hour study . Eight milliliter ( 2 teaspoon ) blood drawn 5 minute 1 minute take CDB-2914 ( either crystalline micronized powder form ) follow time take drug : 15 , 30 , 45 , 60 , 75 , 90 , 105 , 120 , 150 180 minute ( 3 hour ) , 4 , 6 , 8 , 10 , 12 , 24 , 48 , 72 , 96 , 120 hour ( 5 day ) . Participants take meal day hospital ward first 26 hour sample . Inpatients leave hospital 24-hour blood draw return outpatient day 2 5 . At 48-hour time point , additional blood drawn check blood count chemistry , liver kidney function test .</brief_summary>
	<brief_title>Comparison Blood Levels Two Formulations Selective Hormone Receptor Modulator CDB-2914</brief_title>
	<detailed_description>In recent year , compound structurally similar naturally occur steroid examine ability block substitute action naturally occur steroid . On occasion , substance effect , depend tissue examine physiology person receive agent . The development kinds compound , call selective hormone receptor modulators , may provide new treatment target specific organ tissue . One example compound selective estrogen receptor modulator raloxifene , block estrogen action uterus , act like estrogen bone , allow use post-menopausal woman estrogen replacement therapy without require progesterone . This study evaluate progesterone receptor modulator CDB-2914 . Earlier study use single dos compound show slow ovarian uterine development menstrual cycle , induce menses , depend give menstrual cycle . Many steroid improve bioavailability give micronized formulation . Previous study CDB-2914 use crystalline powder dose 200 mg. We wish compare pharmacokinetic profile crystalline micronized CDB-2914 , 10 mg . The drug give single oral dose blood drawn frequently 12 hour daily five day measurement compound .</detailed_description>
	<mesh_term>Progesterone</mesh_term>
	<criteria>INCLUSION CRITERIA : General inclusion criterion : Female genderto evaluate effect target population clinical trial . In good health . Chronic medication use acceptable except glucocorticoid use . Other chronic medication use may acceptable discretion principal investigator . Interval use overthecounter drug acceptable must record . Hemoglobin great 10 g/dL . Willing able comply study requirement . Age 18 50 . Additional inclusion criterion premenopausal woman : Using mechanical ( condom , diaphragm ) , abstinence , oral contraceptive , IUD sterilization method contraception duration study . Because effect CDB2914 IUD efficacy know , woman use form birth control advise use barrier method cycle ( ) participate . Negative urine pregnancy test within one week first study . If second study occur subsequent cycle , pregnancy test repeat . EXCLUSION CRITERIA : Significant abnormality history , physical laboratory examination Pregnancy Lactation Use oral , injectable inhaled glucocorticoid megesterol within last year Unexplained vaginal bleeding History malignancy within past 5 year Use antiepileptic agent</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2005</verification_date>
	<keyword>Progesterone</keyword>
	<keyword>Cortisol</keyword>
	<keyword>Menstrual Cycle</keyword>
	<keyword>Formulation</keyword>
	<keyword>Endometrium</keyword>
	<keyword>Estrogen</keyword>
</DOC>